Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
- Cleo Diagnostics, Chimeric and Orthocell were the week’s biggest movers by magnitude
- Sales contracts and revenue growth drove gains for Cyclopharm, Memphasys and Microba
- Capital raisings and debt funding stayed central as drug developers funded late-stage programs
- US regulatory and commercial milestones remained a key reason investors paid attention
Cleo Diagnostics (ASX:COV) led the week’s biggest moves with a 29.41% fall, even as it moved into analytical validation for its ovarian cancer test ahead of a planned US filing in early 2027. Chimeric Therapeutics (ASX:CHM) lost 15.38% after reporting tumour shrinkage in an early cell therapy study. Orthocell (ASX:OCC) dropped 14.20% despite posting record FY26 revenue of $13.2 million. In plain terms, some of the strongest news did not hold the share price. Early gains faded or sellers took over after the open.
Commercial wins carried more weight
Cyclopharm (ASX:CYC) rose 14.29% after securing an 11-site rollout with University Hospitals Cleveland. Investors cared because this was not a pilot or a small order. It was an immediate hospital network installation that can produce repeat revenue from scans. Memphasys (ASX:MEM) also gained 14.29% after record quarterly revenue and its largest Felix supply deal with Monash IVF. The message was simple: more clinics are paying for the product. Microba Life Sciences (ASX:MAP) added 7.32% after reporting 92% growth in core testing revenue and setting a $7 million annual cost reduction program. The stock reopened higher and then kept climbing, which suggests buyers stayed in the market rather than taking quick profits. Cryosite (ASX:CTE) rose 4.00% on stronger revenue and margins, while Immuron (ASX:IMC) finished flat after a 6% sales lift. For both, the key issue is whether extra capacity and retail growth turn into larger sales over the next year.Trials moved faster, but investors still asked for proof
Neurizon Therapeutics (ASX:NUZ) fell 5.97% even after finishing enrolment in its ALS study in less than five months. Faster enrolment matters because it cuts the wait for results, now due in late Q2 2027. Mesoblast (ASX:MSB) climbed 8.93% after completing treatment of 300 patients in a late-stage back pain trial. EMVision (ASX:EMV) rose 8.00% as its brain scanner trial passed enrolment marks and the company kept $17.1 million in cash. Dimerix (ASX:DXB) expanded its kidney disease pipeline by buying DMX-652, a pill now being prepared for a mid-stage study in acute kidney injury. Island Pharmaceuticals (ASX:ILA) slipped 7.78% after adding Texas Biomed to help refine dosing for Galidesivir ahead of a key Marburg animal study. Investors liked the extra science support, but the stock still fell hard after reopening, which means confidence did not hold through the week.US access remained the main prize
Pacific Edge (ASX:PEB) dropped 6.12% even though it moved closer to Medicare cover for bladder cancer tests. Medicare is the US government health payer for older people. If cover is granted, doctors can order the test knowing reimbursement is more likely. That matters because payment often decides whether test volumes rise. LTR Pharma (ASX:LTP) eased 1.92% after locking in a US launch deal with Shed for at least 150,000 ROXUS units in year one. Neurotech International (ASX:NTI) fell 5.88% despite clearing a US FDA filing for NTI164, which allows US studies to start. CLINUVEL Pharmaceuticals (ASX:CUV) lost 3.41% after winning Health Canada approval for SCENESSE in a rare light-sensitivity disease. Vectus Biosystems (ASX:VBS) gained 9.38% after appointing Cardinal Health to handle US submissions for its fibrosis drug. Cleo, Pacific Edge and Vectus all show the same pattern in different forms: investors pay close attention when a company gets nearer to the US system, because that is where larger healthcare markets and larger reimbursement pools sit.Cash stayed central to the story
Starpharma (ASX:SPL) announced a fully underwritten $32 million entitlement offer at $0.57 a share and ended the week down 0.84%. An entitlement offer gives existing holders the right to buy more shares, usually at a discount. Investors often worry about dilution, which means each existing share represents a smaller slice of the company after new shares are issued. Still, the money should fund the DEP HER2-Lu Phase 1 study and other cancer assets. Paradigm Biopharma (ASX:PAR) drew another US$3 million to support its Phase 3 osteoarthritis trial. Neurotech added a $3.15 million loan backed by future R&D tax incentives, while Orthocell’s $44.1 million cash balance softened concerns about expansion costs. OncoSil Medical (ASX:OSL) rose 9.85% after validating local manufacturing for its device. That matters because making product closer to home can improve supply control and, if volumes rise, can leave more money on each sale. Elsewhere, Rua Bioscience (ASX:RUA) signed a NZ$10 million UK medical cannabis export deal, HeraMED (ASX:HMD) reported strong uptake in a US maternity care pilot, and Recce Pharmaceuticals (ASX:RCE) won a patent in Vietnam. INOVIQ (ASX:IIQ) slipped 4.55% after sample quality issues slowed work on its ovarian cancer test. Immutep (ASX:IMM) lost 1.96% after a strong survival update was offset by the halt of a larger lung cancer study. In both cases, investors had a clear reason to hold back: either the data set was not good enough, or the bigger trial did not work.Bottom Line?
The next tests for the sector are clear: more companies need to turn trial progress into readable results in 2027, convert regulatory steps into paid US sales, and show that new funding can carry programs through their next major milestone.
Questions in the middle?
- Will Orthocell’s strong revenue growth be enough to stop further selling before expected UK and EU clearance later in 2026?
- Can Pacific Edge turn draft Medicare progress into a real jump in US test volumes by 2027?
- After Cleo and INOVIQ hit sample and validation issues, which diagnostics group will be first to show a clean path to a US submission?